Why PsyBio Will be the Leader in the Psychedelic Drug Discovery Industry:
IP Protected Bio synthetic pathway for candidate production
Ability to Manufacture and conduct invitro & invivo efficacy testing and conduct human
clinical trial psychedelic inspired compound discovery and production
Portfolio of psycho-targeted biotherapeutics manufacturing organizations for process development and commercialization of lead
compounds
Robust and expanding intellectual property portfolio encompassing twenty-nine patent submission covering thousands of molecules including compositions of matter, interactions, manufacturing and methods of use.
In preparation for potential clinical partnership(s) for funded human subject clinical trial(s) analyzing
bio-synthetic psilocybin for the treatment of two different mental health conditions.
Second drug candidate in IND preparation exhibiting similar therapeutic properties as psilocybin without the hallucinogenic effect.
PsyBio is one of a small number of companies actively working towards US FDA sanctioned clinical trials in the psychedelic inspired biotherapeutic space.
Milestones
US and EU clinical trial initiation Q4 2023.
FDA and EMA submissions
for US and/or EU clinical trials Q4 2023.
Completed Pre-IND Type C meeting affirming pre-clinical requirements and clinical indications.
Completion of cGMP manufacturing development Q4 2023.
IND preparation for second generation non- hallucinatory drug candidate
PsyBio Advantage: Bio-Medicinal Chemistry
Agricultural Production and Extraction
Chemical Synthetic Production
PsyBio Advantage :
Bio-Synthetic Production
Highly Flexible Biosynthetic Production
STARTING MATERIAL 1
STARTING MATERIAL 2
STARTING MATERIAL 3
STARTING MATERIAL 4
STARTING MATERIAL 5
STARTING MATERIAL 6
purification
purification
purification
purification
purification
purification
FINAL PRODUCT 6
FINAL PRODUCT 5
FINAL PRODUCT 4
FINAL PRODUCT 3
FINAL PRODUCT 2
